Implementing evidence-based guidelines for preventing chemotherapy-induced neutropenia: From paper to clinical practice

Community Oncology

Volumn 3, Issue 8, 2006, Pages 530-536

  Maxwell, Cathy ^a   Stein, Alisha ^b  

^a Advanced Medical Specialties   (United States)

^b Cancer Research Network   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ALGORITHM; ARTICLE; CANCER MORTALITY; CLINICAL PRACTICE; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEALTH PROGRAM; HUMAN; MEDICAL EDUCATION; MORBIDITY; PRACTICE GUIDELINE; RISK ASSESSMENT;

EID: 33749188117     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70747-1     Document Type: Article

References (28)

1. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-2266.
2. Crawford J, Althaus B, Armitage J, et al. Myeloid growth factors. NCCN Clinical Practice Guidelines in Oncology, v.1.2006. Available at: http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf. Accessed June 17, 2006.
3. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update for recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205.
4. Aapro MS, Cameron DA, Pettengell R, el al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. European Organisation for Research and Treatment of Cancer Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. Eur J Cancer 2006. E-Pub ahead of print (doi: 10.1016/j.ejca.2006.05.002).
5. Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 2005;3:557-571.
6. Kuderer NM, Crawford J, Dale DC, Lyman GH. Meta-analysis of prophylactic granulocyte colony-stimulating factor in cancer patients receiving chemotherapy. J Clin Oncol 2005;23(suppl):758s. Abstract 8117.
7. Ardizzoni A, Favaretto A, Boni L, et al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis - a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 2005;23:569-575.
8. Bonadonna G, Moliterni A, Zambetti M, et al. 30 Years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005;330:205-206.
9. Cosler LE, Calhoun EA, Agboola O, Lyman GH. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 2004;24:488-494.
10. Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value Health 2005;8:47-52.
11. Bennett CL, Somerfield MR, Pfister DG, Tomori C, Yakren S, Bach PB. Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. J Clin Oncol 2003;21:937-941.
12. Ozer H, Armitage JO, Bennett CL, et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:3558-3585.
13. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-1184.
14. th Annual Congress of the Oncology Nursing Society, April 18-21, 2002; Washington, DC. Abstract 126.
15. Ambinder EP. ASCO's role in facilitating the adoption of electronic records in oncology. J Oncol Pract 2005;1:64-65.
16. Kozakiewicz JM, Benis LJ, Fisher SM, Marseglia JB. Safe chemotherapy administration: using failure mode and effects analysis in computerized prescriber order entry. Am J Health Syst Pharm 2005;62:1813-1816.
17. Myers JS. Hypersensitivity reaction to paclitaxel: nursing interventions. Clin J Oncol Nurs 2000;4:161-163.
18. McKibben LJ, Stange PV, Sneller VP, Strikas RA, Rodewald LE. Use of standing orders programs to increase adult vaccination rates. Advisory Committee on Immunization Practices. MMWR Recomm Rep 2000;49(RR-1):15-16.
19. Maxwell C. Your practice: implementing standing orders. Presented at the Nurse Advisory Board-July 11, 2003; Naples, Fla.
20. Ray-Coquard I, Philip T, de Laroche G, et al. Persistence of medical change at implementation of clinical guidelines on medical practice: a controlled study in a cancer network. J Clin Oncol 2005;23:4414-4423.
21. Ray-Coquard I, Philip T, Lehmann M, Fervers B, Farsi F, Chauvin F. Impact of a clinical guidelines program for breast and colon cancer in a French cancer center. JAMA 1997;278:1591-1595.
22. Ray-Coquard I, Philip T, de Laroche G, et al. A controlled "before-after" study: impact of a clinical guidelines programme and regional cancer network organization on medical practice. Br J Cancer 2002;86:313-321.
23. White N, Maxwell C, Michelson J, Bedell C. Protocols for managing chemotherapy-induced neutropenia in clinical oncology practices. Cancer Nurs 2005;28:62-69.
24. th Annual Congress of the Oncology Nursing Society; April 18-21, 2002; Washington, DC. Abstract 169.
25. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524-4531.
26. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:4302-4311.
27. Fortner BV, Okon TA, Zhu L, et al. Costs of human resources in delivering cancer chemotherapy and managing chemotherapy-induced neutropenia in community practice. Commun Oncol 2004;1:23-28.
28. Neuss MN, Desch CE, McNiff KK, et al. A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative. J Clin Oncol 2005;23:6233-6239.